Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 16/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | FADS1 | O60427 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19795236 | 0.87 | TRPA1 (0.52) | GRM4CYP1A2FADS1TRPA1 | |
| SCHEMBL19795046 | 0.84 | GRM4 (0.70) | GRM4CYP1A2 | |
| SCHEMBL19795050 | 0.84 | GRM4 (0.49) | GRM4CYP1A2 | |
| SCHEMBL19795051 | 0.76 | GRM4 (0.48) | GRM4CYP1A2 | |
| SCHEMBL19795231 | 0.72 | GRM4 (0.69) | GRM4CYP1A2 | |
| SCHEMBL19795234 | 0.71 | GRM4 (0.48) | GRM4CYP1A2 | |
| SCHEMBL19795194 | 0.71 | GRM4 (0.52) | GRM4FADS1TRPA1 | |
| SCHEMBL19795334 | 0.71 | FADS1 (0.46) | GRM4CYP1A2FADS1TRPA1ADRA2A | |
| SCHEMBL19795076 | 0.70 | GRM4 (0.66) | GRM4CYP1A2 | |
| SCHEMBL19795066 | 0.70 | GRM4 (0.74) | GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRIA4 | GRM4 2/4885CYP1A2 2619/4885FADS1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.